# Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

> **NCT07578649** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 600 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Endometrial Cancer

## Interventions

- **BIOLOGICAL:** PF-08634404
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT07578649
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-09
- **Primary completion:** 2029-06-01
- **Final completion:** 2031-01-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07578649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07578649, "Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07578649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*